Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Asset Writedowns and Impairment (2016 - 2020)

CV Sciences' Asset Writedowns and Impairment history spans 7 years, with the latest figure at $6.2 million for Q4 2020.

  • For Q4 2020, Asset Writedowns and Impairment rose 3031.31% year-over-year to $6.2 million; the TTM value through Dec 2020 reached $6.4 million, up 2633.05%, while the annual FY2023 figure was $251000.0, 79.66% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2020 was $6.2 million at CV Sciences, up from $46000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $6.2 million in Q4 2020 and bottomed at -$47000.0 in Q4 2018.
  • The 5-year median for Asset Writedowns and Impairment is $38001.5 (2016), against an average of $691669.4.
  • The largest annual shift saw Asset Writedowns and Impairment tumbled 156.92% in 2018 before it skyrocketed 3031.31% in 2020.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $2.7 million in 2016, then tumbled by 96.93% to $82565.0 in 2017, then crashed by 156.92% to -$47000.0 in 2018, then surged by 521.28% to $198000.0 in 2019, then surged by 3031.31% to $6.2 million in 2020.
  • Per Business Quant, the three most recent readings for CVSI's Asset Writedowns and Impairment are $6.2 million (Q4 2020), $46000.0 (Q1 2020), and $198000.0 (Q4 2019).